MAC lung disease

AN2 Therapeutics, a biopharmaceutical company, has made the decision to voluntarily pause Phase 3 enrollment in its Phase 2/3 clinical trial for the treatment-refractory MAC lung disease. This pause is pending further data review. Trial Details The double-blind trial consists of two arms. One arm compares epetraborole plus optimized background regimen (OBR), while the other arm … [Read more...] about AN2 Therapeutics Pauses Phase 3 Enrollment in Clinical Trial